SuperworthAgilent Technologies A
- Market cap
- $48.8B
- PE
- 34.0×
- 10y median 33.1×
- Forward PE
- 26.4×
- 10y median 25.1×
- Price to sales
- 6.6×
- EV/EBIT
- 31.1×
- Revenue, 12 months
- $7.4B
- +9% on a year ago
- Net margin
- 19.5%
- Free cash flow yield
- 2.6%
Agilent Technologies trades at 34.0× trailing earnings, near its ten-year median. Revenue was $7.4B over the last twelve months, up 9% on a year earlier with a 20% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.7B−9% | $1.7B−6% | $1.6B−8% | $1.6B−6% | $1.7B+1% | $1.7B+1% | $1.7B+6% | $1.7B+10% | $1.9B+9% | $1.8B+7% | $1.8B+10% | $1.9B+8% | |
| Cost of revenue | $773M−8% | $750M−5% | $717M−10% | $723M−29% | $785M+2% | $782M+4% | $802M+12% | $850M+18% | $871M+11% | $852M+9% | $845M+5% | $836M−2% |
| Gross profit | $915M−10% | $908M−6% | $856M−7% | $855M+30% | $916M+0% | $899M−1% | $866M+1% | $888M+4% | $990M+8% | $946M+5% | $990M+14% | $1B+17% |
| R&D | $114M−4% | $128M+4% | $113M−10% | $127M+8% | $111M−3% | $113M−12% | $112M−1% | $111M−13% | $119M+7% | $117M+4% | $126M+13% | $123M+11% |
| SG&A | $393M−7% | $396M−6% | $380M−8% | $395M−3% | $397M+1% | $410M+4% | $454M+20% | $417M+6% | $428M+8% | $476M+16% | $465M+2% | $475M+14% |
| $408M−13% | $384M−10% | $363M−5% | $333M+150% | $408M+0% | $376M−2% | $300M−17% | $360M+8% | $443M+9% | $353M−6% | $399M+33% | $444M+23% | |
| Interest expense | $22M−4% | $22M−12% | $20M−17% | $22M−8% | $32M+46% | $28M+27% | $29M+45% | $28M+27% | $27M−16% | $25M−11% | $25M−14% | $29M+4% |
| Pre-tax income | $420M−8% | $403M−2% | $374M−1% | $343M+160% | $401M−5% | $367M−9% | $260M−31% | $366M+7% | $442M+10% | $364M−1% | $408M+57% | $444M+21% |
| −$55M | $55M−5% | $66M−12% | $61M+191% | $50M | $49M−11% | $45M−32% | $30M−51% | $8M−84% | $59M+20% | $69M+53% | $82M+173% | |
| Net income | $475M+29% | $348M−1% | $308M+2% | $282M+154% | $351M−26% | $318M−9% | $215M−30% | $336M+19% | $434M+24% | $305M−4% | $339M+58% | $362M+8% |
| $1.60+29% | $1.18−1% | $1.05+3% | $0.97+155% | $1.23−23% | $1.11−6% | $0.75−29% | $1.18+22% | $1.54+25% | $1.07−4% | $1.20+60% | $1.28+9% | |
| 296M−0% | 294M−1% | 293M−1% | 291M−1% | 285M−4% | 287M−2% | 285M−3% | 285M−2% | 282M−1% | 284M−1% | 283M−1% | 283M−1% |
Gross profit: 73 periods, Q3 FY08 to Q3 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 18 periods, Q4 FY08 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 17 periods, Q4 FY08 to Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q4 FY26 | $2B | $2B to $2B | $1.73 | $1.72 to $1.74 | 11 |
| Q1 FY27 | $1.9B | $1.9B to $1.9B | $1.50 | $1.46 to $1.53 | 6 |
| Q2 FY27 | $2B | $1.9B to $2B | $1.61 | $1.59 to $1.62 | 4 |
| Q3 FY27 | $2B | $2B to $2B | $1.73 | $1.71 to $1.75 | 2 |
| Q4 FY27 | $2.1B | $2.1B to $2.1B | $1.87 | $1.86 to $1.90 | 2 |
| Q1 FY28 | $2B | $2B to $2B | $1.64 | $1.63 to $1.66 | 4 |
| Q2 FY28 | $2.1B | $2.1B to $2.1B | $1.75 | $1.74 to $1.77 | 3 |
| Q3 FY28 | $2.1B | $2.1B to $2.1B | $1.85 | $1.84 to $1.87 | 4 |
Peers
Companies in Medical - Diagnostics & Research nearest Agilent Technologies' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| AAgilent Technologies | $48.8B | 34.0× | 33.1× | 26.4× | 6.6× | +9% | 19.5% |
| IQVIQVIA | $46B | 34.7× | 34.9× | 20.5× | 2.7× | +8% | 8.1% |
| WATWaters | $44.6B | 113× | 29.2× | 29.2× | 9.6× | +52% | 3.6% |
| IDXXIDEXX Laboratories | $44.1B | 39.4× | 55.0× | 35.9× | 9.7× | +13% | 25.0% |
| ILMNIllumina | $40.7B | 50.1× | 51.4× | 47.2× | 9.1× | +5% | 18.4% |
| MTDMettler-Toledo International | $33.5B | 37.6× | 36.5× | 33.9× | 8.1× | +7% | 21.9% |
| DGXQuest Diagnostics | $26.7B | 25.7× | 19.3× | n/m | 2.3× | +9% | 9.2% |
| LHLabcorp | $26.7B | 27.2× | 19.4× | 17.4× | 1.9× | +6% | 7.0% |
| MEDPMedpace | $18.7B | 39.2× | 34.5× | n/m | 6.7× | +25% | 17.7% |
| RVTYRevvity | $17.7B | 75.6× | 34.8× | n/m | 6.1× | +4% | 8.2% |
| DHRDanaher | $162B | 40.9× | 34.2× | 25.4× | 6.5× | +5% | 15.9% |
| Peer median | $37.1B | 39.3× | 34.7× | 29.2× | 6.6× | +8% | 12.6% |
Investors who own it
Investors we follow who held Agilent Technologies at the end of Jun 30, 2026, from their 13F filings.
- Ron BaronBaron Capital0.0% of portfolio
More on Agilent Technologies
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #5of 39Diagnostics and research stocks with the highest profit margins
- #5of 20Diagnostics and research stocks with the lowest PE ratio
- #5of 17Diagnostics and research stocks with the fastest earnings growth
- #7of 15Diagnostics and research stocks cheapest against their own PE history
- #6of 11Diagnostics and research stocks with the fastest expected revenue growth
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .